The purpose of Gradientech’s Investor Relations is to continuously inform the capital market about the company’s operations and development. Here you will find press releases and financial reports as well as information about the share and corporate governance.
Latest press releaseAll press releases
Upcoming eventAll events
Rights issue 2023
Gradientech’s Board of Directors have decided to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 25.8 million. The subscription period now runs until and including 6 December 2023. Here you will find all information about the rights issue.
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics that provide patients with the right dose of the right medicine at the right time.
Next-generation antimicrobial susceptibility testingTake a look at our E-book